Zum Inhalt springenZur Suche springen

Kernkompetenzen für Habilitand*innen und Wissenschaftler*innen in frühen Karrierestufen

Die Fakultät misst der kontinuierlichen Weiterbildung von Wissenschaftler*innen in frühen Karrierestufen und einer qualifizierten Betreuung von Doktorandinnen und Doktoranden besondere Bedeutung zu. Der Erwerb von zusätzlichen Schlüsselqualifikationen unterstützt Habilitierende, neben den fachlichen Qualifikationen, in ihrem Forschungsalltag.

Habilitand*innen  sollen sich regelmäßig im Bereich Kernkompetenzen fortbilden und nach Möglichkeit in jedem Jahr vor der Habilitation eine Veranstaltung besuchen (s. Habilitationsordnung).

Für den Antrag zur Habilitation müssen dabei insgesamt mindestens vier Weiterbildungen zu Kernkompetenzen für prom. Wissenschaftler*innen nachgewiesen werden. Davon muss eine Veranstaltung eine Fortbildung zur Sicherung guter wissenschaftlicher Praxis sein. Die Veranstaltungen müssen nicht alle aus verschiedenen Bereichen kommen. Es können auch mehrere Veranstaltungen aus einem Bereich gewählt werden.

Qualifizierungbereiche
Die in der neuen Habilitationsordnung geforderten Weiterbildungen sollen aus folgenden Qualifizierungsbereichen erbracht werden:

  • Karriereentwicklung durch Forschungsförderung, Drittmitteleinwerbung
  • Führung, Führungsstil, Führungspersönlichkeit, Führungsverantwortung
  • Führung im Team, Teamzusammenstellung, Teammoderation, -motivation
  • Wissenschaftsmanagement
  • Personalmanagement
  • Betreuung von Abschlussarbeiten
  • Projekt- und Zeitmanagement
  • Kommunikation
  • Konfliktmanagement
  • Präsentation und Öffentlichkeitsarbeit

Kurse anderer Anbieter werden angerechnet, wenn diese
a) den oben beschriebenen Qualifizierungsbereichen zugeordnet werden können und
b) diese Veranstaltungen für promovierte Nachwuchswissenschaftler*innen konzipiert sind.

GWP-Schulungen
Das Junior Scientist and International Researcher Center (JUNO) organisiert im Auftrag des Graduiertenzentrums Medizin die Veranstaltungen zur guten wissenschaftlichen Praxis für die Habilitanden und Habilitandinnen sowie für die Kandidatinnen und Kandidaten für eine Apl.-Professur. Bei der Antragstellung werden nur die GWP-Schulungen der JUNO oder in Art und Umfang äquivalente Veranstaltungen anderer Standorte berücksichtigt. Die Schulungen der iGRAD bzw. die Schulungen für Medizindoktoranden der medRSD sind nicht für die o.g. Zielgruppe konzipiert und daher ungeeignet.

Academic Career Development Programme (ACDP)
Die Teilnahme am Academic Career Development Programme auf die geforderten Kernkompetenzen für prom.  Wissenschaftler*innen angerechnet. Sie müssen neben der erfolgreichen Teilnahme an dem Mentoring-Programm nur noch die Fortbildung zur guten wissenschaftlichen Praxis nachweisen.

Zertifikatsprogramm 'Betreuung in der Wissenschaft'
Die Teilnahme am Zertifikatsprogramm 'Betreuung in der Wissenschaft' wird auf die geforderten Kernkompetenzen für prom.  Wissenschaftler*innen angerechnet.

Selma-Meyer-Mentoring
Teilnehmerinnen des SelmaMeyerMentoring‐Programms für fortgeschrittene Postdoktorandinnen und Habilitandinnen der HHU (Linien SelmaMeyerMED+, PROF, PROF‐MED) werden die im Programm besuchten Workshops auf die geforderten Kernkompetenzen für prom.  Wissenschaftler*innen angerechnet. Sie müssen neben der erfolgreichen Teilnahme an dem Mentoring-Programm nur noch die Fortbildung zur guten wissenschaftlichen Praxis nachweisen.

Veranstaltungen für promovierte Wissenschaftler*innen

Die Weiterbildungen werden vom Junior Scientist and International Researcher Center (JUNO) zu den nachfolgenden Kompetenzbereichen angeboten. Wählen Sie aus den angebotenen Veranstaltungen von JUNO und melden Sie sich direkt über den Link zur Veranstaltung an.

Paediatric oncology at University Hospital Düsseldorf
US hyperthermia award goes to PD Dr. Rüdiger Wessalowski

Zoom

Photo: PD Dr. Rüdiger Wessalowski, University-Hospital Düsseldorf, Department of Paediatric Oncology, Haematology and Clinical Immunology

This Department in Düsseldorf is currently the only one in the world to also treat children with the targeted overheating of the tumour tissue in combination with chemotherapy and/or radiotherapy. Prof. Dr. Rolf Issels at the Medical Center of the University of Munich (LMU) and PD Dr. Rüdiger Wessalowski are the only German physicians so far to have won this highest distinction by the STM.

Within the framework of experimental and clinical research projects, Wessalowski has developed new treatment concepts for the use of hyperthermia in children in cases where standard therapies are unsuccessful or not sufficiently successful or whose illness returned after standard therapies. In 2013, Wessalowski received the ESHO BSD Award from the European Society for Hyperthermic Oncology. The keynote speech by the 30th recipient of the Robinson award as part of the symposium was entitled “Apoptosis or Necrosis – Mechanisms of Cell Death induced by Hyperthermia”.

 

Background:

How hyperthermia works

Hyperthermia is used to treat patients suffering from cancerous tumours that are not responding or not responding adequately to standard therapies as well as patients who relapse after standard therapies with chemotherapy as well as radiation. Hyperthermia with targeted overheating of the tumour tissue is used additionally. It increases the effectiveness of the two aforementioned therapies, and the thermal effect itself also destroys the tumour. Clinical application of hyperthermia in children was established around 25 years ago in Düsseldorf under the supervision of Prof. Dr. Ulrich Göbel, former Director of the Department of Paediatric Oncology, Haematology and Immunology.

 

J. Eugene Robinson Award

The J. Eugene Robinson Award is presented to acknowledge the work of J. Eugene Robinson, a US doctor who was a pioneer in hyperthermic research. The award is presented each year to researchers who have made outstanding contributions in this field. Robinson himself first used hyperthermia to treat cancerous tumours in the 1960s together with radiation and continued his investigations in various areas related to hyperthermia including thermal dose and time-temperature relationships. 

Autor/in:
Kategorie/n: Auch in Englisch, Forschungsnews Englisch

Paediatric oncology at University Hospital Düsseldorf
US hyperthermia award goes to PD Dr. Rüdiger Wessalowski

Zoom

Photo: PD Dr. Rüdiger Wessalowski, University-Hospital Düsseldorf, Department of Paediatric Oncology, Haematology and Clinical Immunology

This Department in Düsseldorf is currently the only one in the world to also treat children with the targeted overheating of the tumour tissue in combination with chemotherapy and/or radiotherapy. Prof. Dr. Rolf Issels at the Medical Center of the University of Munich (LMU) and PD Dr. Rüdiger Wessalowski are the only German physicians so far to have won this highest distinction by the STM.

Within the framework of experimental and clinical research projects, Wessalowski has developed new treatment concepts for the use of hyperthermia in children in cases where standard therapies are unsuccessful or not sufficiently successful or whose illness returned after standard therapies. In 2013, Wessalowski received the ESHO BSD Award from the European Society for Hyperthermic Oncology. The keynote speech by the 30th recipient of the Robinson award as part of the symposium was entitled “Apoptosis or Necrosis – Mechanisms of Cell Death induced by Hyperthermia”.

 

Background:

How hyperthermia works

Hyperthermia is used to treat patients suffering from cancerous tumours that are not responding or not responding adequately to standard therapies as well as patients who relapse after standard therapies with chemotherapy as well as radiation. Hyperthermia with targeted overheating of the tumour tissue is used additionally. It increases the effectiveness of the two aforementioned therapies, and the thermal effect itself also destroys the tumour. Clinical application of hyperthermia in children was established around 25 years ago in Düsseldorf under the supervision of Prof. Dr. Ulrich Göbel, former Director of the Department of Paediatric Oncology, Haematology and Immunology.

 

J. Eugene Robinson Award

The J. Eugene Robinson Award is presented to acknowledge the work of J. Eugene Robinson, a US doctor who was a pioneer in hyperthermic research. The award is presented each year to researchers who have made outstanding contributions in this field. Robinson himself first used hyperthermia to treat cancerous tumours in the 1960s together with radiation and continued his investigations in various areas related to hyperthermia including thermal dose and time-temperature relationships. 

Autor/in:
Kategorie/n: Auch in Englisch, Forschungsnews Englisch

Paediatric oncology at University Hospital Düsseldorf
US hyperthermia award goes to PD Dr. Rüdiger Wessalowski

Zoom

Photo: PD Dr. Rüdiger Wessalowski, University-Hospital Düsseldorf, Department of Paediatric Oncology, Haematology and Clinical Immunology

This Department in Düsseldorf is currently the only one in the world to also treat children with the targeted overheating of the tumour tissue in combination with chemotherapy and/or radiotherapy. Prof. Dr. Rolf Issels at the Medical Center of the University of Munich (LMU) and PD Dr. Rüdiger Wessalowski are the only German physicians so far to have won this highest distinction by the STM.

Within the framework of experimental and clinical research projects, Wessalowski has developed new treatment concepts for the use of hyperthermia in children in cases where standard therapies are unsuccessful or not sufficiently successful or whose illness returned after standard therapies. In 2013, Wessalowski received the ESHO BSD Award from the European Society for Hyperthermic Oncology. The keynote speech by the 30th recipient of the Robinson award as part of the symposium was entitled “Apoptosis or Necrosis – Mechanisms of Cell Death induced by Hyperthermia”.

 

Background:

How hyperthermia works

Hyperthermia is used to treat patients suffering from cancerous tumours that are not responding or not responding adequately to standard therapies as well as patients who relapse after standard therapies with chemotherapy as well as radiation. Hyperthermia with targeted overheating of the tumour tissue is used additionally. It increases the effectiveness of the two aforementioned therapies, and the thermal effect itself also destroys the tumour. Clinical application of hyperthermia in children was established around 25 years ago in Düsseldorf under the supervision of Prof. Dr. Ulrich Göbel, former Director of the Department of Paediatric Oncology, Haematology and Immunology.

 

J. Eugene Robinson Award

The J. Eugene Robinson Award is presented to acknowledge the work of J. Eugene Robinson, a US doctor who was a pioneer in hyperthermic research. The award is presented each year to researchers who have made outstanding contributions in this field. Robinson himself first used hyperthermia to treat cancerous tumours in the 1960s together with radiation and continued his investigations in various areas related to hyperthermia including thermal dose and time-temperature relationships. 

Autor/in:
Kategorie/n: Auch in Englisch, Forschungsnews Englisch

Paediatric oncology at University Hospital Düsseldorf
US hyperthermia award goes to PD Dr. Rüdiger Wessalowski

Zoom

Photo: PD Dr. Rüdiger Wessalowski, University-Hospital Düsseldorf, Department of Paediatric Oncology, Haematology and Clinical Immunology

This Department in Düsseldorf is currently the only one in the world to also treat children with the targeted overheating of the tumour tissue in combination with chemotherapy and/or radiotherapy. Prof. Dr. Rolf Issels at the Medical Center of the University of Munich (LMU) and PD Dr. Rüdiger Wessalowski are the only German physicians so far to have won this highest distinction by the STM.

Within the framework of experimental and clinical research projects, Wessalowski has developed new treatment concepts for the use of hyperthermia in children in cases where standard therapies are unsuccessful or not sufficiently successful or whose illness returned after standard therapies. In 2013, Wessalowski received the ESHO BSD Award from the European Society for Hyperthermic Oncology. The keynote speech by the 30th recipient of the Robinson award as part of the symposium was entitled “Apoptosis or Necrosis – Mechanisms of Cell Death induced by Hyperthermia”.

 

Background:

How hyperthermia works

Hyperthermia is used to treat patients suffering from cancerous tumours that are not responding or not responding adequately to standard therapies as well as patients who relapse after standard therapies with chemotherapy as well as radiation. Hyperthermia with targeted overheating of the tumour tissue is used additionally. It increases the effectiveness of the two aforementioned therapies, and the thermal effect itself also destroys the tumour. Clinical application of hyperthermia in children was established around 25 years ago in Düsseldorf under the supervision of Prof. Dr. Ulrich Göbel, former Director of the Department of Paediatric Oncology, Haematology and Immunology.

 

J. Eugene Robinson Award

The J. Eugene Robinson Award is presented to acknowledge the work of J. Eugene Robinson, a US doctor who was a pioneer in hyperthermic research. The award is presented each year to researchers who have made outstanding contributions in this field. Robinson himself first used hyperthermia to treat cancerous tumours in the 1960s together with radiation and continued his investigations in various areas related to hyperthermia including thermal dose and time-temperature relationships. 

Autor/in:
Kategorie/n: Auch in Englisch, Forschungsnews Englisch
Verantwortlichkeit: